We are live on
!
Find out more
Ensign Peak Advisors Portfolio holdings
AUM
$53.7B
1-Year Est. Return
29.47%
This Fund
S&P 500
This Quarter
Est. Return
-2.36%
1 Year Est. Return
+29.47%
3 Year Est. Return
+102.45%
5 Year Est. Return
+139.11%
10 Year Est. Return
–
AUM
$46.8B
AUM Growth
-$2.48B
(-5%)
Cap. Flow
-$831M
Cap. Flow
% of AUM
-1.77%
Top 10 Holdings %
Top 10 Hldgs %
28.11%
Holding
1,786
New
25
Increased
394
Reduced
504
Closed
30
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Crown Castle
CCI
|
+$130M |
| 2 |
Amgen
AMGN
|
+$96.1M |
| 3 |
Progressive
PGR
|
+$94.9M |
| 4 |
AbbVie
ABBV
|
+$77.1M |
| 5 |
Kenvue
KVUE
|
+$75.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$148M |
| 2 |
Johnson & Johnson
JNJ
|
+$147M |
| 3 |
LyondellBasell Industries
LYB
|
+$108M |
| 4 |
Dollar General
DG
|
+$91.2M |
| 5 |
ExxonMobil
XOM
|
+$87.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.48% |
| 2 | Healthcare | 17.42% |
| 3 | Financials | 12.53% |
| 4 | Consumer Discretionary | 9.71% |
| 5 | Communication Services | 7.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
451
Prudential Financial
PRU
$43B
| $7.87M | 0.02% |
82,948
-3,386
| -4% | -$320K |
|
452
Equity Lifestyle Properties
ELS
$12.8B
| $7.85M | 0.02% |
123,252
-25,533
| -17% | -$1.72M |
|
453
Energy Transfer Partners
ET
$69.5B
| $7.79M | 0.02% |
555,230
| – | – |
|
454
Tarsus Pharmaceuticals
TARS
$2.57B
| $7.78M | 0.02% |
437,891
+195,440
| +81% | +$3.46M |
|
455
H&R Block
HRB
$5.7B
| $7.76M | 0.02% |
180,254
-97,081
| -35% | -$3.58M |
|
456
Manhattan Associates
MANH
$9.95B
| $7.76M | 0.02% |
39,268
-3,077
| -7% | -$601K |
|
457
Brown & Brown
BRO
$25B
| $7.67M | 0.02% |
109,854
-60,336
| -35% | -$4.3M |
|
|
XYZ
458
Block Inc
XYZ
$49.5B
| $7.66M | 0.02% |
173,101
-6,474
| -4% | -$401K |
|
459
Genuine Parts
GPC
$17.9B
| $7.65M | 0.02% |
52,975
-37,690
| -42% | -$5.85M |
|
460
United Therapeutics
UTHR
$26.1B
| $7.62M | 0.02% |
33,726
-2,084
| -6% | -$480K |
|
461
NVR
NVR
$17.3B
| $7.52M | 0.02% |
1,261
-734
| -37% | -$4.56M |
|
462
MSCI
MSCI
$42.1B
| $7.48M | 0.02% |
14,588
-5,543
| -28% | -$2.91M |
|
463
Syndax Pharmaceuticals
SNDX
$1.74B
| $7.48M | 0.02% |
514,852
+126,500
| +33% | +$2.39M |
|
464
Madrigal Pharmaceuticals
MDGL
$12.4B
| $7.45M | 0.02% |
51,047
+9,850
| +24% | +$1.85M |
|
465
Quest Diagnostics
DGX
$26B
| $7.43M | 0.02% |
60,939
-6,787
| -10% | -$904K |
|
466
Nasdaq
NDAQ
$53.6B
| $7.42M | 0.02% |
152,752
-27,395
| -15% | -$1.39M |
|
467
Fidelity National Financial
FNF
$14.6B
| $7.42M | 0.02% |
179,600
-19,820
| -10% | -$794K |
|
468
Power Integrations
POWI
$3.3B
| $7.37M | 0.02% |
96,525
-990
| -1% | -$84.7K |
|
469
Royal Bank of Canada
RY
$295B
| $7.33M | 0.02% |
83,481
+500
| +0.6% | +$46.5K |
|
470
Ventas
VTR
$47.7B
| $7.33M | 0.02% |
173,934
+44,055
| +34% | +$1.98M |
|
471
Molina Healthcare
MOH
$10.5B
| $7.29M | 0.02% |
22,225
-2,208
| -9% | -$695K |
|
472
Omnicom Group
OMC
$24.6B
| $7.27M | 0.02% |
97,568
+1,600
| +2% | +$132K |
|
473
Repligen
RGEN
$8.2B
| $7.24M | 0.02% |
45,504
+235
| +0.5% | +$38.4K |
|
474
Denali Therapeutics
DNLI
$3.82B
| $7.19M | 0.02% |
348,497
+200,000
| +135% | +$5.07M |
|
|
EXE
475
Expand Energy Corp
EXE
$21.2B
| $7.19M | 0.02% |
83,335
-35,020
| -30% | -$2.97M |
|
Similar funds
SCP
Ensign Peak Advisors's Q3 2023 Portfolio in Review
As of Q3 2023, Ensign Peak Advisors held 1,786 positions worth $46.8B, down 5% from $49.3B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Trading was light in Q3 2023: portfolio turnover was 3.1%. Ensign Peak Advisors opened 25 new positions and exited 30, leaving the 1,786-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 24% of assets, down from 25% a quarter earlier, followed by Healthcare and Financials.
- Ensign Peak Advisors's largest Q3 2023 buy was Invesco QQQ Trust: 160,000 shares worth $57.3M.
- Ensign Peak Advisors added most to Crown Castle in Q3 2023, an estimated $130M increase.
- Ensign Peak Advisors's biggest Q3 2023 reduction was Eli Lilly, cutting an estimated $148M.
- Ensign Peak Advisors fully exited RB Global in Q3 2023, selling an estimated $26.5M.
- Ensign Peak Advisors's ten largest holdings make up 28% of its $46.8B portfolio in Q3 2023.
- Ensign Peak Advisors opened 25 new positions and closed 30 in Q3 2023.
- Ensign Peak Advisors's portfolio value fell 5% quarter-over-quarter to $46.8B.
Based on Ensign Peak Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.